RxDoctor Payments Data

Rexford Babilah, MD

Internal Medicine · Lanham, MDNPI 1689869968

Payments from drug & device makers

$15,646in general payments, 2019–2025

Across 803 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • AbbVie$1K
  • Amgen$1K
  • Lilly USA, LLC$912
  • Pfizer$887
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,28998%
  • Education$3572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk112$1,688
AstraZeneca79$1,505
AbbVie(2 entities)61$1,319
Amgen(2 entities)56$1,080
Lilly USA, LLC56$912
Pfizer45$887
Bayer35$809
Corcept Therapeutics29$698
Astellas Pharma US Inc24$560
Abbott16$554
Novartis27$515
GSK19$379
Lundbeck LLC13$296
Boehringer Ingelheim15$292
Amarin Pharma, Inc.13$263
Sumitomo Pharma America, Inc.11$248
Optinose US, Inc.11$225
Teva Pharmaceuticals USA, Inc.12$207
Endo Pharmaceuticals Inc.13$178
Kowa Pharmaceuticals America, Inc.11$175
Johnson & Johnson8$173
Takeda Pharmaceuticals U.S.A., Inc.11$173
Merck11$158
Ardelyx, Inc.5$157
Avanir Pharmaceuticals, Inc.8$146
Arbor Pharmaceuticals, Inc.10$141
Regeneron Healthcare Solutions, Inc.6$129
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$129
Biohaven Pharmaceuticals, Inc.7$129
Ironwood Pharmaceuticals, Inc9$127
Otsuka America Pharmaceutical, Inc.5$122
Organogenesis Inc.3$100
Xeris Pharmaceuticals, Inc.4$93
Exact Sciences4$90
Global Blood Therapeutics, Inc.4$88
Boston Scientific3$80
Biohaven Pharmaceutical Holding Company Ltd.4$75
Sanofi-aventis U.S. LLC4$73
Alnylam Pharmaceuticals Inc.3$64
CSL Behring2$58
Axsome Therapeutics, Inc.2$50
Antares Pharma, Inc.2$46
Chiesi USA, Inc.2$41
Esperion Therapeutics, Inc.2$40
Inspire Medical Systems, Inc.1$40
Nevro Corp.1$27
Hologic Sales And Service, LLC1$25
Eisai Inc.2$25
Shield Therapeutics Inc1$24
Genentech USA, Inc.1$24
Smith+Nephew1$22
Medtronic1$21
Paratek Pharmaceuticals, Inc.1$18
E.r. Squibb & Sons, L.L.C.1$17
Phadia US Inc.1$17
Currax Pharmaceuticals LLC1$16
Zyla Life Sciences, Inc.1$16
Cumberland Pharmaceuticals, Inc.1$16
Gilead1$16
Azurity Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,646 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$413,254
Medicare patients
364
Services billed
4,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide85$117,362
EliquisApixaban64$82,637
OzempicSemaglutide37$72,752
TrulicityDulaglutide37$66,227
LinzessLinaclotide62$57,375
JardianceEmpagliflozin44$46,133
FarxigaDapagliflozin Propanediol37$43,990
DovatoDolutegravir Sodium/Lamivudine14$40,534
ProliaDenosumab23$39,901
EntrestoSacubitril/Valsartan27$36,358
KerendiaFinerenone19$32,511
RybelsusSemaglutide16$30,001
MyrbetriqMirabegron31$29,474
XareltoRivaroxaban22$27,508
Repatha SyringeEvolocumab23$23,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$912$183,589122 claims
Novo NordiskOzempic, Rybelsus$1,688$102,75353 claims
PfizerEliquis$887$82,63764 claims
AbbVieLinzess$1,319$57,37562 claims
Boehringer IngelheimJardiance, Tradjenta$292$56,55757 claims
AstraZenecaFarxiga$1,505$43,99037 claims
AmgenProlia$1,080$39,90123 claims
NovartisEntresto$515$36,35827 claims
BayerKerendia$809$32,51119 claims
Astellas Pharma US IncMyrbetriq$560$29,47431 claims
Johnson & JohnsonXarelto$173$27,50822 claims
MerckJanuvia$158$22,83717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Lanham

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →